Polidocanol foam sclerotherapy in the treatment of hemorrhoidal disease in patients with bleeding disorders: a multicenter, prospective, cohort study

P Salgueiro, A Rei, M Garrido, B Rosa, A M Oliveira, T Pereira-Guedes, S Morais, F Castro-Poças, P Salgueiro, A Rei, M Garrido, B Rosa, A M Oliveira, T Pereira-Guedes, S Morais, F Castro-Poças

Abstract

Background: The management of hemorrhoidal disease (HD) in patients with bleeding disorders (BD) is challenging. Polidocanol foam sclerotherapy (PFS) is associated with a low rate of bleeding complications. The aim of this study was to compare the efficacy and safety of PFS in the treatment of HD in patients with and without BD.

Methods: This prospective, multicenter, cohort study enrolled patients with (group B) and without (group A) BD, with symptomatic internal HD grades I-III over an 18-month period. All patients were treated with PFS. Patients with congenital BD did not undergo prior replacement therapy and those with acquired BD due to antithrombotic drugs, did not discontinue therapy. Efficacy outcomes included therapeutic success and HD recurrence during a 1-year follow-up period. To evaluate safety the complications related to PFS were recorded.

Results: We included 228 patients (group A: 155, group B: 73; male/female: 114/114; mean age: 59.4 ± 15.9 years). The baseline hemorrhoidal disease bleeding grade (p < 0.001) and Sodergren hemorrhoidal symptom severity score (p = 0.019) were higher for group B. The overall therapeutic success rate was 93.4% with an average number of sessions of 1.51 ± 0.74, significantly higher for group B (1.68 ± 0.86 vs 1.43 ± 0.65, p = 0.013). Complications occurred in 11.4% of the patients, with bleeding reported in 4.8%. The majority of complications were mild (96.2%). No significant differences between the two groups were observed for therapeutic success, recurrence, or complication rate.

Conclusions: Patients with BD may have more symptomatic HD at baseline. Even so, PSF showed similar effectiveness and safety in patients with BD compared to patients without BD.

Keywords: Bleeding disorder; Hemorrhoidal disease; Polidocanol foam; Sclerotherapy.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2022. Springer Nature Switzerland AG.

Figures

Fig. 1
Fig. 1
Polidocanol foam preparation (Tessari´s technique)
Fig. 2
Fig. 2
Schematic representation of polidocanol foam sclerotherapy (according to Blanchard’s technique)
Fig. 3
Fig. 3
Study flowchart. BD: bleeding disorders
Fig. 4
Fig. 4
Participants enrolled in the study (Group B subgroups). ASA aminosalicylic acid, DOAC Direct oral anticoagulants
Fig. 5
Fig. 5
Recurrence Probability (Cox regression)

References

    1. Salgueiro P, Caetano AC, Oliveira AM, Rosa B, Mascarenhas-Saraiva M, Ministro P, et al. Portuguese society of gastroenterology consensus on the diagnosis and management of Hemorrhoidal disease. GE Port J Gastroenterol. 2020;27(2):90–102. doi: 10.1159/000502260.
    1. Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990;98(2):380–386. doi: 10.1016/0016-5085(90)90828-o.
    1. Riss S, Weiser FA, Schwameis K, Riss T, Mittlbock M, Steiner G, et al. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012;27(2):215–220. doi: 10.1007/s00384-011-1316-3.
    1. Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18(17):2009–2017. doi: 10.3748/wjg.v18.i17.2009.
    1. Sun Z, Migaly J. Review of Hemorrhoid disease: presentation and management. Clin Colon Rectal Surg. 2016;29(1):22–29. doi: 10.1055/s-0035-1568144.
    1. van Tol RR, Kimman ML, Melenhorst J, Stassen LPS, Dirksen CD, Breukink SO, et al. European society of coloproctology core outcome set for haemorrhoidal disease: an international delphi study among healthcare professionals. Colorectal Dis. 2019;21(5):570–580. doi: 10.1111/codi.14553.
    1. Qureshi WA. Office management of hemorrhoids. Am J Gastroenterol. 2018;113(6):795–798. doi: 10.1038/s41395-018-0020-0.
    1. Rorvik HD, Styr K, Ilum L, McKinstry GL, Dragesund T, Campos AH, et al. Hemorrhoidal disease symptom score and short health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum. 2019;62(3):333–342. doi: 10.1097/DCR.0000000000001234.
    1. Pucher PH, Qurashi M, Howell AM, Faiz O, Ziprin P, Darzi A, et al. Development and validation of a symptom-based severity score for haemorrhoidal disease: the Sodergren score. Colorectal Dis. 2015;17(7):612–618. doi: 10.1111/codi.12903.
    1. Sha HL, Roslani AC, Poh KS. Evaluating the ability of the Sodergren score to guide the management of internal haemorrhoidal disease. Colorectal Dis. 2020;22(10):1379–1387. doi: 10.1111/codi.15091.
    1. Gallo G, Martellucci J, Sturiale A, Clerico G, Milito G, Marino F, et al. Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. 2020;24(2):145–164. doi: 10.1007/s10151-020-02149-1.
    1. Goligher J DH, Nixon H (1984) Surgery of the anus, rectum and colon. Fifth edition ed. Tindall B, editor. London
    1. Cataldo P, Ellis CN, Gregorcyk S, Hyman N, Buie WD, Church J, et al. Practice parameters for the management of hemorrhoids (revised) Dis Colon Rectum. 2005;48(2):189–194. doi: 10.1007/s10350-004-0921-4.
    1. Jongen J, Kahlke V. Quality indicators in the treatment of hemorrhoids. Chirurg. 2019;90(4):264–269. doi: 10.1007/s00104-018-0787-y.
    1. Rosa B. Polidocanol foam: a breath of fresh air for the treatment of internal hemorrhoids. GE Port J Gastroenterol. 2019;26(3):153–154. doi: 10.1159/000493440.
    1. Cocorullo G, Tutino R, Falco N, Licari L, Orlando G, Fontana T, et al (2017) The non-surgical management for hemorrhoidal disease A systematic review. G Chir 38(1):5–14. 10.11138/gchir/2017.38.1.005
    1. Tutino R, Salamone G, De Marco P, Cocorullo G, Gulotta G. Outpatient treatment of hemorrhoidal disease: the alternative way to treat Hemorrhoidal disease in a simple, safe and effective manner. Rev Recent Clin Trials. 2021;16(1):5–9. doi: 10.2174/1574887115666200305150029.
    1. Albuquerque A. Rubber band ligation of hemorrhoids: a guide for complications. World J Gastrointest Surg. 2016;8(9):614–620. doi: 10.4240/wjgs.v8.i9.614.
    1. Poen AC, Felt-Bersma RJ, Cuesta MA, Deville W, Meuwissen SG. A randomized controlled trial of rubber band ligation versus infra-red coagulation in the treatment of internal haemorrhoids. Eur J Gastroenterol Hepatol. 2000;12(5):535–539. doi: 10.1097/00042737-200012050-00010.
    1. Iyer VS, Shrier I, Gordon PH. Long-term outcome of rubber band ligation for symptomatic primary and recurrent internal hemorrhoids. Dis Colon Rectum. 2004;47(8):1364–1370. doi: 10.1007/s10350-004-0591-2.
    1. Fernandes V, Fonseca J. Polidocanol foam injected at high doses with intravenous needle: The (Almost) perfect treatment of symptomatic internal hemorrhoids. GE Port J Gastroenterol. 2019;26(3):169–175. doi: 10.1159/000492202.
    1. Moser KH, Mosch C, Walgenbach M, Bussen DG, Kirsch J, Joos AK, et al. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial. Int J Colorectal Dis. 2013;28(10):1439–1447. doi: 10.1007/s00384-013-1729-2.
    1. Salgueiro P, Garrido M, Gaio R, Ruben M, Pedroto I, Castro-Poças F. Polidocanol foam sclerotherapy versus rubber band ligation in hemorrhoidal disease Grades I, II and III: randomized trial. Dis Colon Rectum. 2021 doi: 10.1097/DCR.0000000000002117.
    1. Makanjuola A, Balogun OS, Osinowo AO, Adesanya AA, da Rocha JT. Comparison of rubber band ligation with 3% polidocanol injection sclerotherapy for the treatment of internal haemorrhoids at a Nigerian tertiary hospital. Niger Postgrad Med J. 2020;27(4):311–316. doi: 10.4103/npmj.npmj_232_20.
    1. Nastasa V, Samaras K, Ampatzidis C, Karapantsios TD, Trelles MA, Moreno-Moraga J, et al. Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm. 2015;478(2):588–596. doi: 10.1016/j.ijpharm.2014.11.056.
    1. Gallo G, Ronconi M, Trompetto M. Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease. Updates Surg. 2021;73(5):2029–2030. doi: 10.1007/s13304-021-01008-4.
    1. Zheng X, Wei Q, Zhang H. Novel developments in polidocanol sclerotherapy: a review. J Biosci Med. 2018;6:31–41. doi: 10.4236/jbm.2018.68003.
    1. Lobascio P, Laforgia R, Novelli E, Perrone F, Di Salvo M, Pezzolla A, et al. Short-term results of sclerotherapy with 3% polidocanol foam for symptomatic second- and third-degree hemorrhoidal disease. J Invest Surg. 2021;34(10):1059–1065. doi: 10.1080/08941939.2020.1745964.
    1. Lisi G, Campanelli M, Grande S, Milito G, Grande M. Sclerotherapy with 3% polidocanol foam for third- and fourth-degree hemorrhoids as "bridge treatment" during the COVID-19 pandemic in Italy. Int J Colorectal Dis. 2021;36(6):1321–1322. doi: 10.1007/s00384-021-03848-3.
    1. Ronconi MCS, Shieppati M. EndoTHeF: Endoluminal Treatment of Hemorrhoids with Foam. Ann Colorectal Res. 2019;6(4):e86297.
    1. Nelson RS, Ewing BM, Ternent C, Shashidharan M, Blatchford GJ, Thorson AG. Risk of late bleeding following hemorrhoidal banding in patients on antithrombotic prophylaxis. Am J Surg. 2008;196(6):994–999. doi: 10.1016/j.amjsurg.2008.07.036.
    1. Atallah S, Maharaja GK, Martin-Perez B, Burke JP, Albert MR, Larach SW. Transanal hemorrhoidal dearterialization (THD): a safe procedure for the anticoagulated patient? Tech Coloproctol. 2016;20(7):461–466. doi: 10.1007/s10151-016-1481-z.
    1. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21(1):73–77. doi: 10.1007/s11239-006-5580-y.
    1. Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Rev. 2020;39:100619. doi: 10.1016/j.blre.2019.100619.
    1. Albrecht H, Maass LS, Hagel AF, Neurath MF, Konturek PC, Raithel M (2019) Anticoagulant-related gastrointestinal bleeding a real-life data analysis on bleeding profiles, frequency and etiology of patients receiving direct oral anticoagulants versus vitamin K antagonists. J Physiol Pharmacol 10.26402/jpp.2019.6.11
    1. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–1243. doi: 10.1016/S0140-6736(11)61215-4.
    1. Pannach S, Goetze J, Marten S, Schreier T, Tittl L, Beyer-Westendorf J. Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. J Gastroenterol. 2017;52(12):1211–1220. doi: 10.1007/s00535-017-1320-7.
    1. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674–1683e3. doi: 10.1016/j.cgh.2017.04.031.
    1. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–1974. doi: 10.1016/S0140-6736(09)61751-7.
    1. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241–250. doi: 10.7326/0003-4819-143-4-200508160-00005.
    1. Lanas A, Carrera-Lasfuentes P, Arguedas Y, Garcia S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906–12 e2. doi: 10.1016/j.cgh.2014.11.007.
    1. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66(21):2271–2281. doi: 10.1016/j.jacc.2015.09.024.
    1. Tsagianni A, Comer DM, Yabes JG, Ragni MV. Von Willebrand disease and gastrointestinal bleeding: A national inpatient sample study. Thromb Res. 2019;178:119–123. doi: 10.1016/j.thromres.2019.04.017.
    1. Tomaszewski M, Bienz M, Kherad O, Restellini S, Lafleche T, Barkun A, et al. Low endoscopy bleeding risk in patients with congenital bleeding disorders. Haemophilia. 2019;25(2):289–295. doi: 10.1111/hae.13691.
    1. Ingerslev J, Hvid I. Surgery in haemophilia. The general view: patient selection, timing, and preoperative assessment. Semin Hematol. 2006;43(1 Suppl 1):S3–S26. doi: 10.1053/j.seminhematol.2005.11.024.
    1. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg. 2001;27(1):58–60.
    1. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–2065. doi: 10.1111/j.1538-7836.2010.03975.x.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren